Clinical Trials Logo

Spinocerebellar Degenerations clinical trials

View clinical trials related to Spinocerebellar Degenerations.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06397274 Not yet recruiting - Clinical trials for Spinocerebellar Ataxias

Stemchymal® for Polyglutamine Spinocerebellar Ataxia

Start date: June 1, 2025
Phase: Phase 2
Study type: Interventional

The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design. Eligible subjects will receive Stemchymal® through intravenous infusion.

NCT ID: NCT06177626 Not yet recruiting - Clinical trials for Spinocerebellar Ataxias

Impact of Exercise on Eyeblink Conditioning in Spinocerebellar Ataxias

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The goal of this project is to evaluate how aerobic training impacts eyeblink conditioning as a proxy for cerebellar dependent motor learning. The newly developed smartphone application, iBlink, will be used to test participants at home in an effort to improve recruitment and increase the sample size of the study. The investigators hypothesize that aerobic training, but not balance training, will improve eyeblink conditioning in participants with spinocerebellar ataxias. The current study focuses on Aim 3 of this project.

NCT ID: NCT03660917 Not yet recruiting - SCA7 Clinical Trials

Riluzole in Patients With Spinocerebellar Ataxia Type 7

Start date: January 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Spinocerebellar ataxia type 7 (SCA7) belongs to the dominant forms of inherited cerebellar ataxias (CA), being one of the rarest form. SCA7 has no therapeutic options, so that the relentless course, the important visual deficit that accompanies CA, and the possibility of disease development in childhood are pressing unmet needs. The investigators published encouraging data on riluzole in inherited CA other than SCA7. These results prompted off-label use of riluzole in single cases of SCA7 in Italy and United States, suggesting possible efficacy of the drug in this condition.

NCT ID: NCT03378414 Not yet recruiting - Clinical trials for Spinocerebellar Ataxia Type 3

Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia

Start date: December 31, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is verify the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar Ataxia, and in addition, explore the possible mechanisms of UC-MSC therapy in Spinocerebellar Ataxia.